Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;77(4):1288-1291.
doi: 10.1111/all.15188. Epub 2021 Dec 3.

Mast cell activation is associated with post-acute COVID-19 syndrome

Joshua B Wechsler  1 , Melina Butuci  2 , Alan Wong  2 , Amol P Kamboj  2 , Bradford A Youngblood  2
Affiliations

Mast cell activation is associated with post-acute COVID-19 syndrome

Joshua B Wechsler et al. Allergy. 2022 Apr.
No abstract available

Keywords: COVID; inflammation; innate immunity; long covid; mast cells.

PubMed Disclaimer

Conflict of interest statement

J.B.W. provides medical advisory consulting for Allakos, Inc. regarding the use of lirentelimab with eosinophilic gastrointestinal diseases. J.B.W. is not employed by Allakos, Inc. and does not hold stock or stock options, and did not receive consulting fees from Allakos, Inc. for this manuscript; M.B., A.W., A.P.K., and B.A.Y. are employees of and hold stock or stock options in Allakos, Inc.

Figures

FIGURE 1
FIGURE 1
PASC patient sera display a distinct profile of elevated inflammatory cytokines and mast cell‐derived proteases. (A–B) Cytokines, chemokines, or mast cell‐derived proteases in sera from symptomatic PASC (dark blue; n = 13), PAAC (light blue; n = 13), or control (gray; n = 19–20) groups. (C) Spearman correlations for levels of active tryptase, IL‐6 and CXCL1 from panels A, B. (D) ROC curves for active tryptase, CPA3, and IL‐6 using PASC versus PAAC and controls. (E–G) Levels of cytokines and mast cell‐derived proteases in sera from PASC patients (light blue; n = 13), acute COVID‐19 patients (red; n = 19), or controls (gray; n = 19–20). *P < 0.05;**P < 0.01;***P < 0.001;****P < 0.0001; ns=not significant; PAAC, post‐acute asymptomatic COVID‐19; PASC, post‐acute sequelae of COVID‐19
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Demonbreun AR, McDade TW, Pesce L, et al. Patterns and persistence of SARS‐CoV‐2 IgG antibodies in Chicago to monitor COVID‐19 exposure. JCI Insight. 2021;6(9). 10.1172/jci.insight.146148 - DOI - PMC - PubMed
    1. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626‐631. 10.1038/s41591-021-01292-y - DOI - PMC - PubMed
    1. Doykov I, Hallqvist J, Gilmour KC, Grandjean L, Mills K, Heywood WE. ‘The long tail of Covid‐19’ ‐ The detection of a prolonged inflammatory response after a SARS‐CoV‐2 infection in asymptomatic and mildly affected patients. F1000Research. 2020;9:1349. 10.12688/f1000research.27287.2 - DOI - PMC - PubMed
    1. Patterson BK, Guevara‐Coto J, Yogendra R, et al. Immune‐based prediction of COVID‐19 severity and chronicity decoded using machine learning. Front Immunol. 2021;12:700782. 10.3389/fimmu.2021.700782 - DOI - PMC - PubMed
    1. Holmes E, Wist J, Masuda R, et al. Incomplete systemic recovery and metabolic phenoreversion in post‐acute‐phase nonhospitalized COVID‐19 patients: implications for assessment of post‐acute COVID‐19 syndrome. J Proteome Res. 2021;20(6):3315‐3329. 10.1021/acs.jproteome.1c00224 - DOI - PubMed

Grants and funding